India Upholds Erlotinib Patent; Cipla Faces Damages
This article was originally published in Scrip
Executive Summary
A long running patent-related case concerning Roche's anticancer, Tarceva (erlotinib), has gone the Swiss multinational's way, leaving challenger Cipla staring at the prospect of coughing up damages.